Supplemental Data
Files in this Data Supplement:
- Supplemental Data -
Supplemental Table 1 - Carfilzomib and its metabolites identified from patient urine (U) and plasma (P) samples
Supplemental Table 2 - Effect of cytochrome P450 (CYP) inhibitors on the disappearance rate of carfilzomib in cryopreserved human hepatocytes
Supplemental Table 3 - Pharmacokinetic parameters of carfilzomib metabolites...
Supplemental Table 4 - Recovery of carfilzomib, M14, and M15...
Supplemental Table 5 - Least squares mean ratios, 90% geometric confidence intervals...
Supplemental Table 6 - Serious adverse events occurring in 5 patients during the first cycle of co-administration of midazolam and carfilzomib
Supplemental Figure 1 - Time-dependent inhibition of carfilzomib on CYP3A requires NADPH and is resistant to dilution
Supplemental Figure 2 - Plasma concentration (mean + SD) over time profile of carfilzomib at 27 mg/m2